Looking to claim credit, update your profile, access journals, or renew your membership? Log in to your My Account page.

ACR Convergence

ACR Convergence

In Person

Logo

About the Event

Date:November 14–19, 2024

Location:Washington, D.C.

Credit:CME: 209.50, ABIM & ABP MOC: 209.50

On Demand:Available

ACR CONVERGENCE 2025

 

Call for Session Suggestions

The call for session suggestions for ACR Convergence 2025 is open. The deadline to submit a proposal is December 10, 2024, at 11:59 PM ET.

 

Call for Session Suggestions Details

ACR Convergence 2024 is an in-person event, showcasing cutting-edge and timely topics in rheumatology, as well as the prevention, diagnosis, and treatment of rheumatic diseases and related comorbid conditions. ACR Convergence offers hundreds of sessions to educate professionals in every segment of rheumatology. Clinicians, researchers, academicians, practice managers, pediatric rheumatologists, fellows in training, advance practice nurses, physician assistants, physical or occupational therapists: Whatever your role, ACR Convergence is the place to expand your knowledge and skills and pique your curiosity.

Target Audience
Rheumatologists, physicians, and healthcare providers who care for patients with rheumatic diseases, and those interested in or engaged in rheumatology research.

Global Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess their knowledge and competence in various rheumatic diseases and conditions.
  • Support their skills in evaluating and diagnosing patients with rheumatic diseases.
  • Discuss and collaborate on challenging cases with peers.
  • Analyze emerging trends and technologies in rheumatology.
  • Employ evidence-based approaches for managing rheumatic conditions.
  • Identify new approaches and strategies for patient management.
  • Interpret recent clinical trial and research findings.
  • Apply new information from basic and clinical science to improve the care of people with rheumatologic illness.

Program Schedule & Syllabi

ACR Convergence 2024 On-Demand Website

Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.


Registration Fees

See information about ACR Convergence registration fees and timelines.


On-Demand Access

Registration for ACR Convergence 2024 includes on-demand access to scientific session recordings through October 10, 2025. On-demand recordings do not allow for live participation.


Press Registration

The American College of Rheumatology welcomes members of the press to write about research presented at our meetings. Complimentary registration is provided to approved members of the press to allow them to attend sessions on site.
See press registration details


Corporate Support

The ACR thanks the following organizations for their support of these ACR Convergence 2024 Education Tracks:

Diversity, Equity, and Inclusion
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lilly USA, LLC

Lupus
Aurinia Pharmaceuticals Inc.
Genentech, Inc.
UCB, Inc.

 

For information about the previous meeting, see the ACR Convergence 2023 section below.

The following is the total credit available for ACR Convergence 2024:

CME: 209.50

ABIM & ABP MOC: 209.50

The deadline to claim CME credit and MOC points for ACR Convergence 2024 is November 13, 2025, at 11:59 PM ET.

See full accreditation details, disclosures, and credit claiming instructions.

ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

  1. Advisor or review panel member
  2. Consultant
  3. Employee
  4. Officer or Board Member
  5. Grant/research support
  6. Speaker/honoraria includes speakers bureau, symposia, and expert witness
  7. Independent contractor
  8. Executive role and/or ownership interest
  9. Royalties and/or patient beneficiary
  10. Intellectual property/patents
  11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
  12. Private investigator
  13. Expert witness
  14. Equity interest
  15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

Planning Committee Disclosures

Faculty Disclosures

Global Financial Relationships Disclosures

Total credit available for ACR Convergence 2023:
CME: 211.25
ABIM & ABP MOC: 211.25

The deadline to claim CME credit and MOC points for ACR Convergence 2023 was November 9, 2024, at 11:59 PM ET.

For full accreditation information and credit claiming instructions, please see the ACR Convergence CME/MOC and Disclosures page.


Global Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify recent developments in the diagnosis and management of patients with rheumatic diseases
  • Outline new technologies for the treatment of rheumatologic problems
  • Describe potential challenges in the delivery of care to patients with rheumatic diseases and specify possible solutions
  • Utilize new research data to improve the quality of care of patients with rheumatic diseases
  • Summarize recent rheumatology research findings

On-Demand Access

All passes included on-demand access to ACR Convergence 2023 session recordings on the virtual meeting website through October 31, 2024.

We use cookies on our website to improve our service to you and for security purposes. By continuing to use our site without changing your browser cookie settings, you agree to our cookie policy and the use of cookies. See ACR Policies